GoodRx Holdings, Inc. (GDRX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong growth prospects, including a 35% YoY increase in Manufacturer Solutions revenue and strategic investments in e-commerce and subscriptions, despite a slight revenue decline due to timing. Positive trends in Pharma Direct and increasing web traffic, alongside durable partnerships, indicate optimism. However, margin pressures and lower take rates are concerns, but the overall sentiment remains positive due to the company's strategic direction and market expansion efforts. The market cap suggests moderate stock volatility, aligning with a positive prediction.
Key Financial Performance
Full Year Revenue $796.9 million, up 1% year-over-year. The growth was impacted by the Rite Aid bankruptcy and lower volume through one of the integrated savings program partners, which reduced revenue by approximately $35 million to $40 million.
Full Year Adjusted EBITDA $270.5 million, up 4% year-over-year. This reflects disciplined execution and cost management.
Prescription Transactions Revenue $544 million, declined 6% year-over-year. The decline was due to the Rite Aid bankruptcy and lower volume through an integrated savings program partner.
Subscription Revenue $83.8 million, decreased 3% year-over-year. Early adoption of condition-specific subscriptions, particularly around weight loss, started late in 2025 and is expected to contribute more meaningfully in 2026.
Pharma Direct Revenue $151.4 million, up 41% year-over-year. Growth was driven by deepening sell-through at manufacturers and ongoing growth in consumer direct pricing.
Cash on Hand $261.8 million at the end of the year, with approximately $80 million of unused capacity available under the revolving credit facility.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Condition-specific subscriptions: Launched new subscriptions for erectile dysfunction, hair loss, and weight loss, which exceeded expectations. Weight loss subscriptions simplify the journey from consultation to prescription with transparent pricing.
GoodRx Pharma Direct: Evolved Pharma Manufacturer Solutions into GoodRx Pharma Direct, a digital storefront for self-pay and direct-to-consumer strategies. Partnered with Novo Nordisk for Wegovy pill launch, accounting for nearly 20% of self-pay fills in a week.
E-commerce ecosystem expansion: Tripled retail footprint by adding new partners, with 6 of the top 10 retail pharmacies now live on the platform. Order volume increased by 83% quarter-over-quarter.
Employer Direct program: Launched a new program to help employers address gaps in insurance coverage by integrating cash pricing and condition-specific telemedicine solutions.
Pharma Direct revenue growth: Revenue from Pharma Direct grew 41% year-over-year to $151.4 million, driven by deeper manufacturer partnerships and consumer pricing growth.
Retail pharmacy partnerships: Secured direct contracts with 9 of the top 10 retail pharmacies, improving retail margins and expanding independent pharmacy contracting.
Focus on Pharma Direct and subscriptions: Shifting focus to Pharma Direct and subscription offerings for long-term growth, despite near-term impacts on prescription transaction revenue.
Consumer-driven healthcare alignment: Positioning GoodRx to align with trends in consumer-driven healthcare, emphasizing affordability, transparency, and direct-to-consumer access.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Rite Aid bankruptcy impact: The bankruptcy of Rite Aid and lower volume through one of the integrated savings program partners resulted in a revenue impact of approximately $35 million to $40 million for the year, negatively affecting year-over-year growth rates.
Pressure on prescription transactions revenue: The company expects pressure on prescription transactions revenue in 2026 due to trade-offs made to invest more heavily in Pharma Direct and subscription offerings, as well as the lapping impacts from 2025.
Retail pharmacy environment challenges: The broader retail pharmacy environment remains challenged, which has implications for the company's prescription marketplace and partnerships with retail pharmacies.
Decline in monthly active consumers: Monthly active consumers fell 14% in 2025 compared to the prior year, indicating challenges in maintaining user engagement and adoption.
Affordability pressures and policy dynamics: Affordability pressures and policy changes in 2025 reshaped access and pricing, creating challenges in adapting to these shifts in the healthcare landscape.
Tighter insurance coverage: Tighter insurance coverage is fundamentally changing how prescriptions are accessed, forcing patients to play a more active role in medication selection and payment.
Dependence on self-pay strategies: The increasing reliance on self-pay strategies for prescription access creates risks, as it requires significant consumer engagement and may not be sustainable for all demographics.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Projections for 2026: The company expects revenue to be in the range of $750 million to $780 million for the full year 2026.
Adjusted EBITDA for 2026: Adjusted EBITDA is projected to be at least $230 million for 2026.
Pharma Direct Revenue Growth: Pharma Direct revenue is expected to grow at least 30% year-over-year in 2026.
Subscription Revenue Growth: Condition-specific subscription programs, particularly around weight loss, are expected to accelerate significantly and contribute more meaningfully to overall subscription revenue in 2026.
Monthly Active Consumers: Monthly active consumers are expected to flatten sequentially from Q4 2025 through Q4 2026.
Long-term Growth Beyond 2026: The company expects to build momentum throughout 2026 and position itself for growth beyond 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: During the year, the company repurchased approximately 48.9 million shares of its stock at an average price of $4.45 per share, totaling $217.4 million. The company believes that share repurchases are a signal of management's confidence in the company's future and are the most efficient method of returning capital to shareholders.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you elaborate on the revenue guidance, particularly the pressure in PTR and the stabilizing MAC rate?
A:The decline in PTR is driven by three factors: non-recurring revenue from Rite Aid and other programs in 2025, a shift of claims to Pharma Direct, and a decline in unit economics due to negotiated lower fees. This is aimed at achieving longer-term durability and predictability. The MAC rate is modeled to remain relatively flat, ending 2026 at about 5.2%. The focus is on stabilizing volume and optimizing relationships with pharmacies, PBMs, and members.
Q:How does the reduction in revenue impact EBITDA guidance, and what portion is due to investments versus new economics?
A:The reduction in EBITDA is partly due to lapping impacts from 2025, such as the loss of Rite Aid revenue, and partly due to elective decisions to invest aggressively for long-term stabilization. No specific line item guidance was provided.
Q:Have you observed any changes in pharma budget spending, particularly in terms of size, duration, or ramp time of new Pharma Direct programs?
A:Contrary to some industry trends, GoodRx has seen pharma budgets being pulled forward in the sales cycle. Pharmaceutical manufacturers continue to invest in direct-to-consumer programs, and bookings in Pharma Direct are up compared to the same time last year.
Q:Is there a shift in the business model towards manufacturing direct, and what is the future of the legacy business?
A:The core Rx Marketplace remains foundational, but the business is evolving to include direct relationships with pharmacies and a focus on Pharma Direct and Employer Direct programs. This shift aligns with consumer demand for direct experiences and regulatory trends, aiming for more durable margins and market alignment.
Q:What is driving the decline in PTR revenue, and is it due to lower take rates or script degradation?
A:The decline in PTR revenue is primarily due to lower take rates, as the company renegotiates for longer-term durability. The volume of scripts is relatively stable, with a slight decline modeled for 2026.
Q:What is the status of partnerships with pharmaceutical manufacturers like Lilly, and how does GoodRx position itself in the direct-to-consumer space?
A:GoodRx continues to engage with pharmaceutical manufacturers, emphasizing the benefits of integrating direct programs within its platform. Manufacturers are exploring direct-to-consumer models but face challenges in setting up consumer-facing operations. GoodRx provides data to demonstrate the advantages of its platform for consumer engagement.
Q:How does the guidance reflect potential margin pressure, and what is the impact on gross margins, SG&A, and R&D?
A:Margin pressure is influenced by the mix of business, with newer offerings like Pharma Direct and condition-specific subscriptions having lower margins than the core business. The expense profile is expected to remain consistent or slightly down as a percentage of revenue, with elective investments in growth areas.
Q:What is the focus on driving MAC volume through HCP relationships, and has the strategy evolved?
A:GoodRx focuses on a broad swath of HCPs, driven by manufacturer relationships and prescriber interests. The strategy has not significantly changed, and HCP engagement remains a key area of focus.
Q:How is sales and marketing being deployed in 2026, and can the company absorb top-line pressures through reduced intensity?
A:Sales and marketing efforts are being redirected towards specific programs, with a focus on condition-specific subscriptions. The company monitors ROAS closely and adjusts spending to optimize returns. Marketing spend as a percentage of revenue is expected to remain consistent or slightly reduced.
Q:What is the strategy for monetizing the generic side of the business?
A:The focus is on engaging consumers and ensuring GoodRx is the preferred program at retail counters. The strategy emphasizes consumer engagement rather than optimizing generics specifically.
Q:How does the company ensure price stability in the business medium-term, given the investment in price concessions?
A:GoodRx is taking a longer-term approach by leveraging Pharma Direct to share brand economics with retailers, creating a more durable relationship and mitigating the race to the bottom on admin fees.
Q:What is the impact of volume reduction in integrated savings programs (ISP), and what behaviors are driving this?
A:There is no new volume reduction; volumes are relatively stable with a slight decline modeled for 2026. Regulatory changes and macroeconomic factors like unemployment and Medicaid eligibility are being monitored for potential impacts.
Q:How is web traffic and app usage evolving with the new subscription offerings, particularly weight loss?
A:Web traffic and app usage are increasing, driven by interest in GLP-1 drugs and new subscription offerings. The launch of the Wegovy pill has significantly boosted engagement, and brand price page views are up year-over-year.
Q:What is the penetration of active brands in Pharma Direct, and how durable are these budgets?
A:GoodRx has approximately 200 manufacturer partnerships, with about 100 brands in point-of-sale cash programs. Revenue is concentrated on top brands like GLP-1s, and budgets are expected to remain durable.
Q:What is the growth outlook for new subscription offerings like weight loss, and how does this inform marketing spend?
A:Condition-specific subscriptions, particularly weight loss, are expected to grow significantly, with a potential 4-5x increase in run rate revenue by the end of 2026. Marketing spend is being directed to support these programs and their halo effect on the brand.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the question about partnerships with specific pharmaceutical manufacturers like Lilly, providing a general response about industry trends and GoodRx's positioning instead of specific details.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Manufacturer Solutions
Pfizer
Pharma Manufacturer
Weight
adoption
affordability access
commercialization
condition subscription
consumer healthcare
consumer prescription
consumer strategy
customer acquisition
decision making
driver
dysfunction hair
evolution
fulfillment
gap
impact
infrastructure
journey
launch
manufacturer pricing
pay consumer
pay price
pay strategy
prescription transaction
price TrumpRx
priority consumer
role GoodRx
scale
self pay
strategy access
strategy consumer
strength
subscription offering
therapy
weight loss
GDRX Transcript
GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call summary and Q&A indicate strong growth in Pharma Direct and condition-specific subscriptions, with optimistic guidance for 2026. Despite some uncertainties in partnerships and PTR revenue, the overall sentiment is positive due to expected revenue and EBITDA growth, as well as strong demand for GLP-1 therapies. The market cap suggests moderate stock price reaction, leading to a 'Positive' prediction (2% to 8%).
GoodRx Holdings, Inc. (GDRX) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call reveals strong growth prospects, including a 35% YoY increase in Manufacturer Solutions revenue and strategic investments in e-commerce and subscriptions, despite a slight revenue decline due to timing. Positive trends in Pharma Direct and increasing web traffic, alongside durable partnerships, indicate optimism. However, margin pressures and lower take rates are concerns, but the overall sentiment remains positive due to the company's strategic direction and market expansion efforts. The market cap suggests moderate stock volatility, aligning with a positive prediction.
GoodRx Holdings, Inc. (GDRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
GoodRx Holdings, Inc. (GDRX) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call summary and Q&A indicate strong growth prospects, particularly in manufacturer solutions and strategic initiatives, despite some headwinds like Rite Aid bankruptcy. The positive sentiment is reinforced by management's optimistic guidance and strategic focus on market expansion and partnerships. The market cap suggests a moderate reaction, leading to a 'Positive' prediction for stock price movement.
GDRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
